Somewhat Positive Press Coverage Somewhat Unlikely to Affect MannKind (MNKD) Stock Price

Headlines about MannKind (NASDAQ:MNKD) have trended somewhat positive on Saturday, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MannKind earned a daily sentiment score of 0.03 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 44.9681238075744 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

MannKind (NASDAQ MNKD) traded down $0.10 on Friday, hitting $2.41. 1,665,688 shares of the company were exchanged, compared to its average volume of 2,720,000. The company has a debt-to-equity ratio of -0.43, a quick ratio of 0.28 and a current ratio of 0.31. The company has a market capitalization of $276.85, a P/E ratio of -8.93 and a beta of 3.08. MannKind has a twelve month low of $0.67 and a twelve month high of $6.96.

MannKind (NASDAQ:MNKD) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.11). The business had revenue of $2.04 million for the quarter, compared to the consensus estimate of $2.56 million. MannKind had a negative return on equity of 24.93% and a negative net margin of 155.83%. The company’s quarterly revenue was down 98.7% on a year-over-year basis. During the same period last year, the firm earned $1.30 earnings per share. equities analysts anticipate that MannKind will post -1.13 earnings per share for the current fiscal year.

A number of equities analysts have weighed in on MNKD shares. HC Wainwright reaffirmed a “buy” rating on shares of MannKind in a research note on Wednesday, November 8th. Maxim Group reaffirmed a “hold” rating on shares of MannKind in a research note on Wednesday, November 1st. Zacks Investment Research downgraded shares of MannKind from a “hold” rating to a “sell” rating in a research note on Wednesday, December 13th. BidaskClub downgraded shares of MannKind from a “hold” rating to a “sell” rating in a research note on Friday, December 22nd. Finally, ValuEngine downgraded shares of MannKind from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 14th. Four research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $0.92.

In other MannKind news, VP Stuart A. Tross purchased 39,840 shares of the company’s stock in a transaction that occurred on Thursday, December 21st. The stock was acquired at an average cost of $2.52 per share, with a total value of $100,396.80. Following the completion of the purchase, the vice president now directly owns 59,840 shares in the company, valued at approximately $150,796.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.10% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/01/13/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-mannkind-mnkd-stock-price.html.

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.

Insider Buying and Selling by Quarter for MannKind (NASDAQ:MNKD)

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply